Recent Progress is Staggering

09.27.13 | By

From programs that provide access to medicines, to the development of innovative new treatments, the recent progress we’ve made is staggering.

Patient Health, Innovation and the Protections Needed

09.27.13 | By

Millions of patients around the world depend on innovative medicines to help them live long, healthy lives. Every time I travel to a different country, I am reminded of this fact. Just last week in Tokyo, PhRMA EVP for Advocacy Chip Davis specifically addressed how the innovative new medicines our member companies develop have enhanced the country’s health care system.

PhRMA Conversations - Medicare Part D and its Promise

09.25.13 | By

In 2003, the Medicare Prescription Drug, Improvement, and Modernization Act was passed by Congress and signed into law by President George W. Bush. This landmark legislation created the Medicare prescription drug benefit (Part D) – a federal program that provides affordable drug coverage to millions of seniors and people with disabilities.

Patients Are Critical Collaborators In Parkinson's Disease

09.25.13 | By

Without patients who volunteer to participate in clinical trials, new medicines (including the 444 medicines in development to prevent and treat neurological disorders such as Parkinson’s) cannot be approved.  The Michael J.

Alzheimer's Disease and the Path Forward

Join Us for a Discussion about Challenges and Opportunities In Pre-Competitive Partnerships, Clinical Trial Enrollment and Public Policy

Conversations on Innovations in the Biopharmaceutical Pipeline

09.23.13 | By

With more than 5,000 medicines in development globally, the prospects for incredible breakthroughs in medicine – many of which may one day help those suffering from diseases that are currently untreatable – are exceedingly bright.

Recognizing World Alzheimer's Day

09.23.13 | By

As the nation recognizes World Alzheimer’s Day this Saturday, the federal government announced that it is awarding a $33.2 million grant to test an Alzheimer’s medicine in pre-symptomatic seniors (60 to 75 year olds) with two copies of the AD gene.  According to a 

Giving Patients Hope

09.20.13 | By

As Senior VP of Communications Matt Bennett noted on the Catalyst this week, years of hard work go into developing and testing new medicines, and this perseverance has resulted in great progress in clinical trial research.

FDA Spends $182k to Monitor Social Media While Biopharma Industry Waits for Social Media Guidance

09.20.13 | By

In this austere fiscal environment, I must admit to being a little surprised by the news that the Food and Drug Administration (FDA) is spending $182,000 on a tool to monitorwhat people are saying about the Agency on social media. 

Clinical Trials Data Sharing in Europe

09.20.13 | By

A new paper released this week highlights issues surrounding the discussions on clinical trial data & The paper Clinical Trials and Data Transparency: The Public Interest Case, highlights specific problems to the current draft European Medicines Agency (EMA). Among the problems highlighted were gaps in the protection of patient privacy, further bureaucratization of an already bureaucratic  system and conflicting policies on regulatory data protection. 

Pages

Subscribe to RSS - Opinion